Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 6/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29930316 | 1.00 | ALDH1A1 (0.62) | ALDH1A1MAPTLMNAHTTHPGD | |
| SCHEMBL2725729 | 0.94 | MAPT (0.59) | ALDH1A1MAPTLMNAHTTHPGD | |
| SCHEMBL11142367 | 0.89 | ALDH1A1 (0.74) | ALDH1A1HPGDAKR1C3NPC1SMN1; SMN2 | |
| SCHEMBL78465 | 0.82 | ALDH1A1 (0.65) | ALDH1A1LMNAHPGDAKR1C3NPC1 | |
| SCHEMBL7819571 | 0.82 | LMNA (0.51) | ALDH1A1MAPTLMNAHTTHPGD | |
| SCHEMBL171739 | 0.80 | ALDH1A1 (0.62) | ALDH1A1LMNAHTTHPGDAKR1C3 | |
| SCHEMBL14683865 | 0.80 | ALDH1A1 (0.62) | ALDH1A1HPGDAKR1C3NPC1SMN1; SMN2 | |
| SCHEMBL1656668 | 0.80 | ALDH1A1 (0.68) | ALDH1A1HPGDAKR1C3NPC1SMN1; SMN2 | |
| SCHEMBL1507158 | 0.80 | ALDH1A1 (0.62) | ALDH1A1LMNAHPGDAKR1C3NPC1 | |
| SCHEMBL1171241 | 0.80 | ALDH1A1 (0.62) | ALDH1A1HPGDAKR1C3NPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11147926-B2 | Intrathecal baclofen pharmaceutical dosage forms and related delivery system | PIRAMAL CRITICAL CARE, INC. (US) | 2021-10-19 | — | — | US | claimed |
| CN-115043768-A | Method for synthesizing N-aryl pyrrolidine-2-ketone by acid-promoted ring opening of cyclopropyl | 新乡市润宇新材料科技有限公司 | 2022-09-13 | — | — | CN | disclosed |
| EP-3275440-B1 | NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | NAT CT GERIATRICS & GERONTOLOGY (JP) | 2022-05-04 | — | — | EP | disclosed |
| US-10813900-B2 | Baclofen formulations and methods for making same | SAOL INTERNATIONAL LIMITED (BM) | 2020-10-27 | — | — | US | disclosed |
| CN-111683932-A | Compound with BET inhibition activity, preparation method and application thereof | 上海海和药物研究开发有限公司 | 2020-09-18 | — | — | CN | disclosed |
| US-20200078327-A1 | BACLOFEN FORMULATIONS AND METHODS FOR MAKING SAME | SAOL INTERNATIONAL LIMITED (BM) | 2020-03-12 | — | — | US | disclosed |
| US-10420740-B2 | Baclofen formulations and methods for making same | SAOL INTERNATIONAL LIMITED (BM) | 2019-09-24 | — | — | US | disclosed |
| US-20190054050-A1 | BACLOFEN FORMULATIONS AND METHODS FOR MAKING SAME | SAOL INTERNATIONAL LIMITED (BM) | 2019-02-21 | — | — | US | disclosed |
| US-10076506-B2 | Baclofen formulations and methods for making same | SAOL INTERNATIONAL LIMITED (BM) | 2018-09-18 | — | — | US | disclosed |
| US-10071068-B2 | Sustained release oral dosage forms of an R-baclofen prodrug | XENOPORT, INC. (US) | 2018-09-11 | — | — | US | disclosed |
| WO-2004085047-A2 | PRODUCTION OF N-(METHYL-ARYL)-2-LACTAM, N-(METHYLCYCLOAKLYL)-2-LACTAM AND N-ALKYL-2-LACTAM | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004085347-A2 | PRODUCTION OF N-ARYL-2-LACTAM AND N-ALKYL-2-LACTAM BY REDUCTIVE AMINATION OF LACTONES WITH ARYL AND ALKYL NITRO COMPOUNDS | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040192936-A1 | PRODUCTION OF N-ARYL-2-LACTAM AND N-ALKYL-2-LACTAM BY REDUCTIVE AMINATION OF LACTONES WITH ARYL AND ALKYL NITRO COMPOUNDS | E. I. DU PONT DE NEMOURS AND COMPANY | 2004-09-30 | — | — | US | disclosed |
| US-20040192932-A1 | Production of N-(methyl aryl)-2-lactam, N-(Methyl cycloalkyl)-2-lactam and N-alkyl-2-lactam by reductive amination of lactones with aryl and alkyl cyano compounds | E.I. DU PONT NEMOURS AND COMPANY | 2004-09-30 | — | — | US | disclosed |
| US-20040192937-A1 | PRODUCTION OF N-ARYL-2-LACTAM AND N-CYCLOALKYL-2-LACTAM BY REDUCTIVE AMINATION OF LACTONES WITH ARYL AMINES | E. I. DU PONT DE NEMOURS AND COMPANY | 2004-09-30 | — | — | US | disclosed |
| EP-0839805-B1 | Pyrrolidinone derivatives and their use as antipsychotic medicaments | SCHERING AG (DE) | 2001-10-04 | — | — | EP | disclosed |
| US-5969138-A | ANTIPSYCHOTIC AGENTS | MITSUI CHEMICALS, INC. (JP) | 1999-10-19 | — | — | US | disclosed |
| EP-0839805-A1 | Pyrrolidinone derivatives and their use as antipsychotic medicaments | MITSUI TOATSU CHEMICALS, INC. (JP) | 1998-05-06 | — | — | EP | disclosed |
| US-5538985-A | SIDE EFFECT REDUCTION | MITSUI TOATSU CHEMICALS, INC. (JP) | 1996-07-23 | — | — | US | disclosed |
| EP-0668275-A1 | Pyrrolidinone derivatives | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1995-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11147926-B2 | Intrathecal baclofen pharmaceutical dosage forms and related delivery system | SLC6A11, SLC6A1, GABRB1 | ALDH1A1 1614/4885MAPT 806/4885LMNA 1903/4885 |
| US-20190054050-A1 | BACLOFEN FORMULATIONS AND METHODS FOR MAKING SAME | GABRE, GABRP, PLCB1 | ALDH1A1 3778/4885MAPT 1719/4885LMNA 4556/4885 |
| US-10076506-B2 | Baclofen formulations and methods for making same | GABRE, GABRP, PLCB1 | ALDH1A1 3778/4885MAPT 1719/4885LMNA 4556/4885 |
| US-20040192937-A1 | PRODUCTION OF N-ARYL-2-LACTAM AND N-CYCLOALKYL-2-LACTAM BY REDUCTIVE AMINATION OF LACTONES WITH ARYL AMINES | NIT2, AAAS, ASNS | ALDH1A1 1338/4885MAPT 3886/4885LMNA 2071/4885 |
| US-10071068-B2 | Sustained release oral dosage forms of an R-baclofen prodrug | GABRB2, GABRB3, GABBR2 | ALDH1A1 1439/4885MAPT 2583/4885LMNA 4249/4885 |
| US-20200078327-A1 | BACLOFEN FORMULATIONS AND METHODS FOR MAKING SAME | GABRE, GABRP, PLCB1 | ALDH1A1 3778/4885MAPT 1719/4885LMNA 4556/4885 |
| US-10420740-B2 | Baclofen formulations and methods for making same | GABRE, GABRP, PLCB1 | ALDH1A1 3778/4885MAPT 1719/4885LMNA 4556/4885 |
| US-20040192936-A1 | PRODUCTION OF N-ARYL-2-LACTAM AND N-ALKYL-2-LACTAM BY REDUCTIVE AMINATION OF LACTONES WITH ARYL AND ALKYL NITRO COMPOUNDS | NIT2, NANS, ASNS | ALDH1A1 1455/4885MAPT 4252/4885LMNA 2179/4885 |
| US-20040192932-A1 | Production of N-(methyl aryl)-2-lactam, N-(Methyl cycloalkyl)-2-lactam and N-alkyl-2-lactam by reductive amination of lactones with aryl and alkyl cyano compounds | AAAS, ASNS, NIT2 | ALDH1A1 2902/4885MAPT 4535/4885LMNA 1594/4885 |
| US-10813900-B2 | Baclofen formulations and methods for making same | GABRE, GABRP, PLCB1 | ALDH1A1 3778/4885MAPT 1719/4885LMNA 4556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.